Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-epitope TARP Peptide DC Vaccine in Stage D0 Prostate Cancer
NCT02362451Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Feb 2020
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of TARP dendritic cell vaccine in prostate cancer (PCa) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Change in the Slope Log of Prostate-specific Antigen Pre vs Post Treatment. Started Jul 2015; status: terminated.
02
Drugs
TARP dendritic cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02362451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362451.